Revolution Medicines, Inc. Intangible Assets, Net (Excluding Goodwill)
Revolution Medicines, Inc. (RVMD) had Intangible Assets, Net (Excluding Goodwill) of $55.80 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-05
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $55.80M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $55.80M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $55.80M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $55.87M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $55.80M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $55.80M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $55.80M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $55.87M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $56.14M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $56.40M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $56.67M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $56.94M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $57.20M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $57.47M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $57.74M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $58.01M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $58.27M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $58.54M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $58.81M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $58.54M 10-Q · filed 2023-05-08 | $59.08M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $59.34M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $59.61M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $59.88M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $60.14M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $60.41M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $60.68M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $60.95M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $61.21M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $61.48M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $61.75M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $62.01M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |